1. Home
  2. |Professionals
  3. |Brett Everett

Brett Everett

Senior International Trade Specialist II | He/Him/His
Senior International Trade Specialist II | He/Him/His
YmV2ZXJldHRAY3Jvd2VsbC5jb20=
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Brett Everett is a senior international trade specialist II in Crowell & Moring's Los Angeles office. He has over ten years of experience as a Licensed Customs Broker with a primary focus on trade with Asia. He has experience with client inquiries into the classification of merchandise under the Harmonized Tariff Schedule of the United States, antidumping/countervailing orders and circumvention, Section 232, and Section 301 matters. Brett has developed compliance and audit programs and has experience with Post Entry Correction filings, protests, and other filings with U.S. Customs and Border Protection (CBP).

He supports clients with import regulatory matters pending primarily before CBP in all areas of import regulatory compliance, customs valuation, country of origin and marking, trade preference programs and free trade agreements, and CBP inquiries (i.e., CF-28s and CF-29s).

Career & Education

    • California State University, Long Beach, B.A.
    • California State University, Long Beach, B.A.

    • Mandarin
    • Mandarin

Brett's Insights

Blog Post | 10.07.26

White House Issues Dual Section 232 Proclamations on Pharmaceuticals and Metals

On April 2, 2026, President Trump signed two presidential proclamations invoking Section 232 of the Trade Expansion Act of 1962 and Section 604 of the Trade Act of 1974 to impose significant new tariffs on imports of patented pharmaceuticals and pharmaceutical ingredients, and to restructure the existing tariff regime for aluminum, steel, and copper articles and their derivatives. The pharmaceutical proclamation targets patented drugs and active pharmaceutical ingredients (APIs), citing the Secretary of Commerce’s finding that approximately 53 percent of patented pharmaceutical products distributed domestically are produced outside the country, and only 15 percent of patented APIs by volume are domestically produced for the U.S. market. The metals proclamation amends three prior Section 232 actions — Proclamation 9704 of March 8, 2018 (aluminum), Proclamation 9705 of March 8, 2018 (steel), and Proclamation 10962 of July 30, 2025 (copper) — to restructure how tariffs are calculated and which derivative articles are covered.  The administration also issued two separate fact sheets for these actions....

View All Insights

Practices

Brett's Insights

Blog Post | 10.07.26

White House Issues Dual Section 232 Proclamations on Pharmaceuticals and Metals

On April 2, 2026, President Trump signed two presidential proclamations invoking Section 232 of the Trade Expansion Act of 1962 and Section 604 of the Trade Act of 1974 to impose significant new tariffs on imports of patented pharmaceuticals and pharmaceutical ingredients, and to restructure the existing tariff regime for aluminum, steel, and copper articles and their derivatives. The pharmaceutical proclamation targets patented drugs and active pharmaceutical ingredients (APIs), citing the Secretary of Commerce’s finding that approximately 53 percent of patented pharmaceutical products distributed domestically are produced outside the country, and only 15 percent of patented APIs by volume are domestically produced for the U.S. market. The metals proclamation amends three prior Section 232 actions — Proclamation 9704 of March 8, 2018 (aluminum), Proclamation 9705 of March 8, 2018 (steel), and Proclamation 10962 of July 30, 2025 (copper) — to restructure how tariffs are calculated and which derivative articles are covered.  The administration also issued two separate fact sheets for these actions....

View All Insights